{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076612","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.274515+00:00","generated_at":"2026-05-15T23:45:31.904468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Definium Therapeutics FY2025 cash $411.6M; Phase 3 MDD trial fully enrolled, topline late Q2 2026","bullets":["Cash, cash equivalents and investments of $411.6M as of Dec 31, 2025, up from $273.7M in 2024; expected to fund operations into 2028.","Phase 3 MDD trial Emerge fully enrolled (149 patients); topline data anticipated late 2Q 2026.","Phase 3 GAD trial Voyage ~80% enrolled, no sample size increase needed; topline early 3Q 2026.","Phase 3 GAD trial Panorama enrollment on track; topline 2H 2026. Sample size re-estimation update on April 22 Investor Day.","Completed $259M equity financing in Q4 2025; appointed new CFO, CCO, and board member Roger Adsett."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076612","json":"https://secwatch.observer/filing/0001193125-26-076612.json","markdown":"https://secwatch.observer/filing/0001193125-26-076612.md","text":"https://secwatch.observer/filing/0001193125-26-076612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/0001193125-26-076612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/dftx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:45:31.904468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}